VIVE Stock Overview
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr0.78|
|52 Week High||kr3.03|
|52 Week Low||kr0.57|
|1 Month Change||14.12%|
|3 Month Change||-30.09%|
|1 Year Change||-73.41%|
|3 Year Change||-85.05%|
|5 Year Change||-73.43%|
|Change since IPO||-97.03%|
Recent News & Updates
|VIVE||SE Biotechs||SE Market|
Return vs Industry: VIVE underperformed the Swedish Biotechs industry which returned -22.1% over the past year.
Return vs Market: VIVE underperformed the Swedish Market which returned -22% over the past year.
|VIVE Average Weekly Movement||8.7%|
|Biotechs Industry Average Movement||9.7%|
|Market Average Movement||7.3%|
|10% most volatile stocks in SE Market||12.7%|
|10% least volatile stocks in SE Market||4.6%|
Stable Share Price: VIVE is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: VIVE's weekly volatility (9%) has been stable over the past year.
About the Company
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer.
Vivesto Fundamentals Summary
|VIVE fundamental statistics|
Is VIVE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VIVE income statement (TTM)|
|Cost of Revenue||kr44.09m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 25, 2022
|Earnings per share (EPS)||-0.22|
|Net Profit Margin||-409.18%|
How did VIVE perform over the long term?See historical performance and comparison
Is VIVE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VIVE?
Other financial metrics that can be useful for relative valuation.
|What is VIVE's n/a Ratio?|
Price to Sales Ratio vs Peers
How does VIVE's PS Ratio compare to its peers?
|VIVE PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
ATORX Alligator Bioscience
EGTX Egetis Therapeutics
MVIR B Medivir
Price-To-Sales vs Peers: VIVE is good value based on its Price-To-Sales Ratio (14.5x) compared to the peer average (22.1x).
Price to Earnings Ratio vs Industry
How does VIVE's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Sales vs Industry: VIVE is good value based on its Price-To-Sales Ratio (14.5x) compared to the Swedish Biotechs industry average (24.5x)
Price to Sales Ratio vs Fair Ratio
What is VIVE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||14.5x|
|Fair PS Ratio||6.7x|
Price-To-Sales vs Fair Ratio: VIVE is expensive based on its Price-To-Sales Ratio (14.5x) compared to the estimated Fair Price-To-Sales Ratio (6.7x).
Share Price vs Fair Value
What is the Fair Price of VIVE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate VIVE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate VIVE's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Vivesto forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if VIVE's forecast earnings growth is above the savings rate (0.4%).
Earnings vs Market: Insufficient data to determine if VIVE's earnings are forecast to grow faster than the Swedish market
High Growth Earnings: Insufficient data to determine if VIVE's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: VIVE's revenue (60.3% per year) is forecast to grow faster than the Swedish market (11% per year).
High Growth Revenue: VIVE's revenue (60.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VIVE's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Vivesto performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VIVE is currently unprofitable.
Growing Profit Margin: VIVE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VIVE is unprofitable, and losses have increased over the past 5 years at a rate of 10.6% per year.
Accelerating Growth: Unable to compare VIVE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VIVE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).
Return on Equity
High ROE: VIVE has a negative Return on Equity (-17.93%), as it is currently unprofitable.
Discover strong past performing companies
How is Vivesto's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: VIVE's short term assets (SEK250.8M) exceed its short term liabilities (SEK39.4M).
Long Term Liabilities: VIVE's short term assets (SEK250.8M) exceed its long term liabilities (SEK4.3M).
Debt to Equity History and Analysis
Debt Level: VIVE is debt free.
Reducing Debt: VIVE has no debt compared to 5 years ago when its debt to equity ratio was 55.6%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VIVE has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: VIVE has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.3% each year
Discover healthy companies
What is Vivesto current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VIVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VIVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VIVE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VIVE's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as VIVE has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Christer Nordstedt (60 yo)
Dr. Christer Nordstedt, M.D., Ph D., serves as Acting Chief Executive Officer at Vivesto AB since July 21, 2022. He serves as Chairman of the Board at WntResearch AB since 2022.He is engaged as a consulta...
Experienced Management: VIVE's management team is considered experienced (2.6 years average tenure).
Experienced Board: VIVE's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20%.
Vivesto AB's employee growth, exchange listings and data sources
- Name: Vivesto AB
- Ticker: VIVE
- Exchange: OM
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr417.522m
- Shares outstanding: 538.04m
- Website: https://www.vivesto.com
Number of Employees
- Vivesto AB
- Gustav III:s Boulevard 46
- 5th floor
- Stockholm County
- 169 73
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/09 00:00|
|End of Day Share Price||2022/08/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.